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Abstract. Foot infections are a common and serious problem in persons with diabetes. Persistent 
ulcers in patients with diabetic foot syndrome in 85% of cases lead to amputation because of 
secondary infection and growing gangrene that significantly worsen the prognosis. The review 
provides the information on the spectrum of microorganisms, initiating the development of 
clinical and morphological forms of diabetic foot infections. Special attention has been paid to the 
choice in diabetic foot infections antibacterial medications based on indicators of sensitivity to 
them by allocated microorganisms and features of therapeutic concentrations formation in the 
skin, soft tissues or bone. Clinical data of researchers in the degree of penetration of various 
antibacterial agents in soft tissue and depend on severity lesions. In our review, it was shown that 
the most common pathogen was Staphylococcus aureus, followed by Pseudomonas aeruginosa, 
Enterobacteriaceae: E. coli, Proteus spp., Klebsiella pneumoniae, Enterobacter spp., and 
Acinetobacter spp. due to multidrug-resistant organisms, such as extended-spectrum beta-
lactamase-producing Gram-negative rods or methicillin-resistant Staphylococcus aureus have 
emerged as substantial problem. Data on the frequency and the sensitivity of key pathogens in 
diabetic foot differ in Russian and foreign researchers, which causes the necessary treatment 
considering local peculiarities allocated pathogens and the degree of  penetration of anti-infective 
agents in the affected tissues.  
Keywords: diabetic foot syndrome, infection, antibiotics, antibiotic resistance, tissue penetration 
of antibiotic. 
  
Over the past decade, the world number of 
patients with diabetes mellitus has increased more 
than 2 times, and reached 387 million people by the 
end of 2014. According to the prognosis of the 
International Diabetes Federation, nearly 592 million 
people will suffer from diabetes by 2035 [1]. 
Pathogenesis of noninsulin dependent diabetes 
mellitus is insulin resistance, which is the cause of many 
metabolic disorders, including hyperglycaemia, 
hypertriglyceridaemia raising low-density lipoprotein, 
decrease in high-density lipoprotein, is activated by the 
process of lipid peroxidation and hyperhomocysteinemia. 
As a result, of these changes is the development of 
endothelial dysfunction, which leads to the appearance of 
neuropathy and angiopathy [2, 3]. 
One of the late complications of diabetes 
mellitus is a diabetic foot syndrome, which includes a 
set of pathological changes on the foot and the lower 
limbs characterized by the development of diabetic 
foot ulcer, neuropathic osteoarthropathy, diabetic 
neuropathy and inflammation or purulence 
complications in patients with DM. This requires 
optimization approaches to complex 
pharmacotherapy [4, 5, 6, 7, 8, 9]. 
Persistent ulcers in 85% of cases lead to 
amputation because of secondary infection and 
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growing gangrene, which dictates the need for 
epidemiological studies for identification of patients 
with diabetic foot infections (DFI), determination of 
both the structure of isolated microorganisms and 
their sensitivity. 
According to Russian authors, predominant 
species in patients with DFI was Gram-positive cocci 
– Staphylococcus aureus. Most common gram-
negative rods were distinguished nonfermenting 
gram-negative rods - Pseudomonas aeruginosa and 
Enterobacteriacae spp.: Escherihia coli, Proteus 
mirabilis. Other Enterobacteriacae in suppurative 
complications of diabetic foot syndrome were less 
frequent. Also anaerobes was detected in in patients 
with DFI [10]. 
Data on the frequency of main pathogens in DFI 
differ in Russian researchers. In the study of the 
frequency pathogens in a "Diabetic foot" office of 
South-Western District of Moscow it was shown, that 
it was dominated  Gram-positive cocci (72%), which 
were presented mainly by staphylococci: S. aureus - 
47%, other (coagulase negative) staphylococci - 23% 
[11]. S. aureus was isolated in 63.2% of cases in a 
Clinical Hospital at the Orenburg station for the 
period 2007-2012 [12]. 
In the study of the structure of pathogens in the 
department of wounds and wound infections the AV 
Vishnevsky Institute of Surgery in Moscow S. aureus 
was distinguished in 21.3-23.5% of cases while the 
number of S. epidermidis was identified from 17.0% 
to 14.3% cases for the period 2012-2015 [13].  
The structure of the isolated microorganisms in 
patients with DFI, admitted to the clinic of North-
Western State Medical University named after I.I 
Mechnikov, dominated by strains of S. aureus, 
amounting to about one-third of all isolates (31.6%). 
Staphylococcus epidermidis was detected in 16,3% 
cases [14]. In other regions of Russia S. aureus and 
coagulase-negative staphylococci are registered in 
28% of cases [15].  
Data on the frequency of detection of 
Enterococcus spp. ranged from 6.2% to 14,3-16% 
cases [14, 15, 16]. In the AV Vishnevsky Institute of 
Surgery the number of E. faecalis strains was 
increased from 6.5% to 16.0% for the period 2012-
2015 [13]. According to researchers same regions of 
Russia E. faecalis is registered in 12% of cases, E. 
cloacae 16% of cases [17]. 
The frequency of gram-negative pathogens, 
represented mainly by Enterobacteriaceae and 
Pseudomonas aeruginosa, detected Russian 
researchers have varied. Among Gram-negative rods, 
amounted to only 28% out of all microorganisms, 
were dominated Enterobacteriacae (Proteus mirabilis, 
Escherihia coli, Klebsiella pneumoniae, Enterobacter 
spp., and others) in 12% cases, as well as non-
fermentative bacteria (Pseudomonas aeuruginosa, 
Acinetobacter spp.) in 14% cases. In 5 patients (9%) 
were detected Pseudomonas aeruginosa [11]. 
According to the research team Division of 
wounds and wound infections AV Vishnevsky 
Institute of Surgery in patients with different forms of 
acute and chronic purulent infection in 
noninsulindependent diabetes mellitus, including DFI 
for the period of 2012-2015, was revealed a slight 
increase in strains of Gram-negative pathogens by 
Enterobacteriacae (Escherihia coli, Klebsiella 
pneumonia, Proteus mirabilis) from 3.2% to 12.6%, 
while the number of non-fermenting bacteria 
(Pseudomonas aeruginosa, Acinetobacter spp.) was 
decreased from 11.3 % to 7.6% strains [13]. In the 
structure of Gram-negative organisms, it was 
identified Pseudomonas aeruginosa (15.3%), 
Escherichia coli (9.2%) and Proteus mirabilis (6.1%) 
by researchers from St. Petersburg. Acinetobacter 
and Enterobacter were presented in small amounts 
(by 3.1%, respectively) [14]. 
During the analysis of pathogens structure in 
DFI in selected regions of the Russian Federation for 
the period 2009-2013, it was found that gram-
negative microorganisms were determined in 29.3% 
of cases. It were predominated Pseudomonas 
aeruginosa (12.8%). Out of Enterobacteriacae were 
isolated Escherichia coli (6.1%), Proteus spp. (6.7%), 
Citrobacter diversus (2.4%), Acinetobacter 
baumannii in 2 cases (1.2%) [15]. 
Data on the frequency fungi varied from 2.4 % 
cases to 8.5% cases in the study different researches 
[13, 15]. 
The most common infecting microorganism 
isolated in in a tertiary care hospital in Jakarta was S. 
aureus (47.5%), followed by Pseudomonas spp. 
(16.9%), E. coli (10.2%), Streptococcus spp. (8.5%), 
Enterobacter spp. (7.0%), Proteus spp. (6.7%), and 
Acinetobacter spp. (3.2%). Overall, 37.2% of the 
diabetic foot infection caused by a single 
microorganism, and 62.8% had polymicrobial 
infections [18]. 
In a multicenter, prospective study conducted in 
Turkey showed that of the 522 strains isolated from 
patients with infectious complications of diabetic foot 
syndrome in 36.4% registered Gram-positive 
pathogens, of which prevailed S. aureus (11.4%). 
Gram-negative pathogens constituted 60.2% of all the 
cases, and most often identified microorganism was 
Escherichia coli (15%) [19]. 
In some researchers, the type of isolated 
microorganism depends on the depth of the ulcer 
process. Gram-positive cocci predominated in 
outpatient treatment of superficial diabetic ulcer or ulcer 
extension without abscess or osteomyelitis. According 
Wagner's classification the most common disease in this 
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patients was grade 1-2. In case more severe lesions 
(deep tissue infection, gangrene) increases the 
proportion of gram-negative bacteria and anaerobes. 
Gram-negative rods were found mostly in patients with 
chronic, previously treated wounds. In case previously 
inpatient treatment for 7-10 days it was showed the 
prevalence of gram-positive microorganisms: S. aureus 
– in 8 cases (33.3%), and coagulase-negative 
staphylococci – in 7 cases (29.2%). Gram-negative 
bacteria P. aeruginosa presented in 4 cases (20.8%), 1 
strain of P. mirabilis (4,2%) was isolated. Candida fungi 
were inoculated in 3 cases (12.5%) Also, it was 
increased the average number of pathogens allocated 
from one patient [11, 12, 15]. 
It was shown by Russian researches that in 
patients were treated in the department of surgical 
infections during the year more than once, and had 
received previous at least one course of antibiotic 
therapy, structure of the microorganisms was 
significantly different compared with structure of the 
microorganisms ulcers in patients hospitalized first 
time. According Wagner's classification the most 
common disease was grade 3-4. The predominant 
species was Staphylococcus aureus, P. aeruginosa, A. 
baumanii. Biofilm was verified in 76% of patients 
hospitalized more than once a year, only 6% of 
hospitalized patients for the first time [10].  
It was found, that the most frequent agent DFI in 
patient without surgical treatment was S. aureus, 
which had resistance to meticillin in 13.5% cases.  
There was a significant frequency of gram-negative 
rods in patients without surgical treatment. The vast 
majority of DFI in patients with previous surgical 
treatment are caused by S. aureus. Percentage of S. 
aureus, which had resistance to meticillin was 
significantly higher (39.3% cases). Also 1.5-2 times 
more common to appear Pseudomonas aeruginosa, 
Acinetobacter baumanii and Enterococcus faecalis, as 
compared with the primary patients [16]. 
Until the most recent decade, the majority of 
studies on the microbiology of DFI were conducted 
in North America and Europe. In recent years, 
investigations in warm climates (especially India, but 
also the Middle East and Africa) have found the most 
common isolates to be Gram-negative rods, 
particularly Pseudomonas aeruginosa. We can only 
speculate on the reasons for this disparity, but they 
may include a hot climate causing foot sweating, the 
use of poor footwear, a high incidence of patient self-
treatment with antimicrobials, frequent foot washing, 
and suboptimal perineal/hand hygiene. Thus, 
clinicians in these regions should consider covering 
Enterobacteriaceae and Pseudomonas spp, pending 
culture and sensitivity results [12]. 
In recent years DFI caused by multidrug-
resistant organisms, such as extended-spectrum beta-
lactamase-producing Gram-negative rods or 
methicillin-resistant S. aureus (MRSA) have emerged 
as substantial problem. Infection with an antibiotic-
resistant organism certainly requires the selection of 
an agent active against that isolate, but should not 
otherwise alter therapeutic management [20, 21]. 
Many researchers of Russia registered the 
highest level of methicillin resistant staphylococcus. 
The analysis sensitivity allocated pathogens in 
patients with different forms acute and chronic 
purulent infection in patient with diabetes mellitus, 
including purulent complications of diabetic foot for 
the period 2012-2015, being treated the AV 
Vishnevsky Institute of Surgery revealed the 
sensitivity of all isolated strains of gram-positive to 
vancomycin. It is shown that the number of MRSA 
decreased in 2015 to 43% against 48% in 2012, while 
the number of methicillin-resistant coagulase-
negative staphylococci (methicillin-resistant S. 
epidermidis, MRSE) increased by 2.5 times - from 
28% in 2012 to 71% in 2015 g. [13]. 
The level of MRSA in patients with DFI were 
treated in Smolensk and Smolensk region in 2005-2008. 
was 49% of cases [22]. According to study of the 
certain regions of Russia antibiotic susceptibility of 
grampositive strains recorded increase of resistance to 
oxacillin in isolated strains of S. aureus and coagulase-
negative staphylococci for 2009-2013. It was shown the 
increase in the number of MRSA from 20% of cases in 
2009 to 50% of cases in 2013. The same trend was 
observed among strains of coagulase-negative 
staphylococci. In 2009-2011 up to 25% of MR-CNS 
were isolated, in 2013 – up to 66.6% of resistant strains. 
In the case of incomplete eradication of infections and 
repeated bacteriological examination of hospitalized 
patients level of MRSA and MR-CNS is much higher 
than the initial, and ranged from 66.6% of cases in 2011 
and 2012 to 100% in 2009 and 2013 [15]. undergoing 
in-patient treatment. 
Some researchers have shown that on an 
outpatient treatment prevalence of MRSA was 
extremely high (62% of strains S. aureus). MR-CNS 
were less common: 29% out of coagulase-negative 
staphylococci. The proportion of methicillin-resistant 
staphylococci (MRSA + MR-CNS) among all agents 
was 35%. One out of 26 Staphylococcus aureus 
(3.8%) was resistant to vancomycin [11]. 
According to foreign authors, the level of S. 
aureus resistance to oxacillin ranged from 0% of 
resistant strains isolated from patients undergoing 
treatment of diabetic foot syndrome in the surgical 
department of Ouagadougou hospital (Burkina Faso) 
up to 100% resistance in strains isolated from 
patients, undergoing treatment at the central hospital 
in Mexico City [23, 24]. 
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Data on the frequency of detection of 
Enterococcus spp. and its resistance vary greatly among 
different authors and 7,1- detected in 16% of cases 
detected Enterococcus spp. [13, 14, 15], which is a bit 
less than the level obtained by US researchers Lipsky 
B.A. et al., 2012 [25]. According to the authors from 
same regions the Russian Federation, enterococcus was 
not allocated in patients with DFI [14, 22].  
Selected strains of Enterococcus spp. Russian 
researchers 52% were resistant to ampicillin at a 
detectable sensitivity to vancomycin [15]. According 
to Shailesh K. Shahi 71.4% strains of Enterococcus 
spp. were resistant to vancomycin [26].  
It was shown by the researchers from Portugal 
that all isolates Enterococci were considered 
multidrug-resistant, cytolysin and gelatinase 
producers, and the majority also demonstrated the 
ability to produce biofilms. It was found that 
polymicrobial communities produced higher biofilm 
values than individual species. 
Pseudomonas + Enterococcus, 
Acinetobacter + Staphylococcus and 
Corynebacterium + Staphylococcus produced higher 
biofilm than the ones formed by E. 
faecalis + Staphylococcus and E. 
faecalis + Corynebacterium [27]. 
The high resistance level of P. aeruginosa was 
detected in some regions of the Russian Federation. It 
was shown  resistance strains P. aeruginosa to 
amikacin in 64.5% strains, ciprofloxacin - 96% 
strains, imipenem - 69% strains, ceftazidime - 33% 
strains. High levels of resistance are characterized 
isolates of A. baumanii that was resistant to amikacin 
in 68% of cases, ciprofloxacin - 99% of cases, 
imipenem - 82% of cases, ceftazidime - 33% of 
cases. All non-fermenting bacteria isolated strains 
showed sensitivity to meropenem [28].  
In some regions of Russia Pseudomonas 
aeruginosa sensitivity to antibiotics was registered an 
increase in resistance level to β-lactams. Thus, the 
sensitivity to cefepime reduced from 100% in 2009-
2011 up to 33.3-66.6% in 2012-2013, at the same 
time there revealed a low sensitivity to ceftazidime, 
which was 50% in 2009, and 33.3% in 2011-2013. 
All isolated strains of P. aeruginosa showed 
sensitivity to meropenem and imipenem, except for 
one strain isolated in 2012, resistant to meropenem. 
We revealed a low sensitivity of P. aeruginosa to 
amikacin and gentamicin: from 0% of strains isolated 
in 2010-2011 up to 50% of strains isolated in 2012-
2013 were susceptible to amikacin. Sensitivity to 
gentamicin varied from 33.3% to 66.6% at the 
preserved sensitivity to netilmicin, which ranged 
from 66.6% up to 100%. We recorded a low level of 
sensitivity to fluoroquinolones: P. aeruginosa 
sensitivity to ciprofloxacin ranged from 50% to 
66.6%, with the exception of strains isolated in 2011, 
which showed 100% sensitivity. We revealed a 
reduction in sensitivity to levofloxacin from 100% in 
2009-2010 up to 50-66.6% in 2011-2013 [15].  
In comparison with the data by Privolnev V.A., 
2011, there was an increase in Pseudomonas 
aeruginosa resistance to cephalosporins, 
fluoroquinolones and aminoglycosides, in contrast to, 
in particular, netilmicin and less amikacin and 
gentamicin revealed in the studied period [22]. 
According to the researchers of the Vishnevsky 
Institute of Surgery among gram-negative bacteria 
was a slight increase in the number of 
Enterobacteriaceae while the number of P. aeruginosa 
was reduced. All isolates of P. aeruginosa showed 
sensitivity to colistin, piperacillin / tazobactam [13]. 
In patients were hospitalized in the clinic of 
North-Western State Medical University named after 
I.I Mechnikov, St. Petersburg P. aeruginosa was 
revealed resistance to gentamicin (66.7%), 
ceftazidime (53.3%), ciprofloxacin (46.7%), 
amikacin (33.3%). The highest activity was detected 
in imipenem, which revealed 22.0% of resistant 
strains [14]. 
Data on Russian researchers in hospitalized 
patients not subjected to a complete eradication 
strains of Pseudomonas aeruginosa revealed on 
repeated bacteriological examination having showed 
the presence of a reduced sensitivity to 
cephalosporins, ranging from 0% to 100% at the 
preserved high sensitivity to imipenem – in 100% of 
cases. Sensitivity to meropenem was found in 50% of 
P. aeruginosa strains, and variative sensitivity to 
gentamicin and amikacin was recorded. In 2010-2011 
the amikacin-resistant strains were revealed. In 2009 
and 2012-2013 up to 50% of strains staying 
susceptible to amikacin with continuously reducing 
sensitivity to fluoroquinolones, which was 100% in 
2011, 50% in 2012, 100% for ciprofloxacin and 0% 
for levofloxacin in 2013. These high variations in 
sensitivity values are, probably, due to a small 
number of isolated strains and identify a trend of the 
developing resistance [15].  
Identification of resistant strains of P. aeruginosa 
under incomplete eradication is consistent with 
Chinese researchers, who showed the relationship 
between multi-resistant microflora isolated in patients 
with DFI, and a higher incidence of amputation in 
33.3% of cases as compared with 8.7% of 
amputations in case of strains with no signs of multi-
resistance [30]. 
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Identified strains of Acinetobacter baumannii in 
the 1.4% -4.2% of cases showed a high level of 
resistance to different groups of antibacterial drugs. 
Revealed resistance to penicillins, cephalosporins, 
fluoroquinolones, aminoglycosides. In 100% of the 
marked sensitivity of the microorganism to 
carbapenems [13, 14, 15, 17, 29]. 
Carbapenemases in Enterobacteriaceae are not 
detected in most regions of Russia and isolated 
strains showed sensitivity to carbapenems [11, 12, 
13, 14, 15, 22, 31]. 
In some regions registered resistance K. 
pneumoniae to imipenem up to 18% of cases with 
persistent sensitivity to meropenem [29]. 
Many authors shows the growing resistance of 
pathogens Enterobacteriacae to cephalosporins, due 
to the production of β-lactamase-producing extended 
spectrum (ESBL) [13, 22]. Especially many (70%) 
strains producing ESBL were among K. pneumoniae. 
Among the amount of E. coli ESBL producers has 
increased from 32% to 45%. It showed a high level of 
resistance of Enterobacteriaceae to fluoroquinolones 
in K. pneumoniae, E. coli, P. mirabilis [13]. 
According to researchers of Smolensk P. 
mirabilis resistant to cephalosporins was 36,4% E. 
coli to cefotaxime, ceftazidime - 40%, cefepime - 
46.7% [22]. 
In a study of the sensitivity of Enterobacteriaeae 
in the clinic of North-Western State Medical 
University named after I.I Mechnikov in the period 
2009-2012 among strains of E. coli were resistent to 
amoxicillin / clavulanate were 44.4%, to 
ciprofloxacin and cefotaxime 33.3%, respectively. 
Among the P. mirabilis resistant to amoxicillin / 
clavulanate was 50% of the strains to ciprofloxacin - 
33.3% of the strains. 
According to some authors identified E. coli and 
other enteric bacteria were sensitive to all antibiotics 
used, which may indicate infection of the wound with 
diabetic foot syndrome in the community [11]. 
It was detected by the authors of the some 
regions of the Russian Federation Enterobacteriaceae 
were resistant to gentamicin at the continuing 
sensitivity to other antibacterial agents [15]. 
It is shown that an increase in the number of 
hospital admissions has changed not only the 
bacterial spectrum of wounds, but also the resistance 
of pathogens to antibiotics, one reason for that is a 
bacterial film [32]. 
In the study of the Zaporozhye researchers the 
cause of pyo-necrotic complications of DFI were 
gram-positive flora in 56,9% of cases, in 33,3% – 
gram-negative, in 2,9% – anaerobes, in 2,3% – fungi. 
The phenomenon of resistance to the major 
antimicrobial drugs was revealed in 65 (37,4%) 
bacteria. Pseudomonas aeruginosa, Staphylococcus 
aureus, Staphylococcus epidermidis, Esherihia coli, 
Acinetobacter baumannii, Enterococcus faecalis had 
the greatest resistance. Among the groups with the 
identified Pseudomonas aeruginosa, 66,0% of the 
bacteria were characterized by a phenotype of 
resistance to carbapenems, 33,0% of which were 
panresistant ones. In patients with Staphylococcus 
aureus in 60,5% of cases the gene of MRSA with 
three genetic variations differed by resistance to 
certain groups of antibiotics was revealed. The most 
important was panresistant one (4,3%) [33]. 
According Indian researchers antibiotic 
susceptibility test of 142 aerobic bacteria revealed 
that 38 (26.76%) were resistant to antibiotics 
belonging to three or more classes. Henceforth, these 
38 isolates were designated as MDR bacteria. 
Prevalence of resistance to different antibiotics 
among the isolates was; cefazolin (65.78%), cefoxitin 
(73.68%), cefoperazone (34.21%), cefepime 
(68.42%), gentamycin (94.73%), amikacin (50%), 
kanamycin (92.10%), streptomycin (65.78%), 
spectinomycin (73.52%), piperacillin/tazobactam 
(26.31%), ampicillin (89%), clindamycin (34.21%), 
tetracycline (60.52%), meropenem (76.31%), 
trimethoprime (63.15%), and co-trimoxazole 
(76.31%). 71.4% of Enterococcus spp. were resistant 
to vancomycin whereas all the Staphylococcus spp. 
were resistant to methicillin [34]. 
According to Pakistani investigators 
Pseudomonas aeruginosa were isolated from 34.8% 
of patients and was sensitive to ceftazidime, 
imipenem, ciprofloxacin and gentamicin in 2009-
2011 [35]. 
In the research of ciprofloxacin concentrations 
in the interstitial fluid of patients infectious diabetic 
foot complications during microdialysis was showed 
that after intravenous administration of 0.2 mg of 
ciprofloxacin revealed no significant differences in 
its penetration into the inflamed and unaffected 
tissue. [36]  
According to German researchers in the study of 
the degree of penetration of levofloxacin in affected 
tissues in patients with diabetic foot syndrome it was 
shown that after oral treatment of levofloxacin 
concentration in wound necrotic tissue was 2.33-
23.23 mg / kg and 0.12-6.41 mg / L in plasma. 
Tissue-to-serum ratios of levofloxacin concentrations 
were >1.0 [37]. 
In the study moxifloxacin penetration by 
intravenously or orally once a day at a dose of 400 
mg per day was determined in tissue samples of 
infected necrotic wounds resected diabetic foot after 
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4-8 days of treatment. Average concentrations of 
moxifloxacin in the necrotic tissue of infected 
diabetic foot wounds after orally or intravenously 
amounted to 1,79 ± 0,82 and 2,20 ± 1,54 g / g, which 
exceeds the minimum inhibitory for Staphylococcus 
aureus and Escherichia coli [38]. 
In the research of Hamada Y. and others, 2015 
showed that the concentration of vancomycin in serum 
and interstitial tissue using microdialysis shown that the 
degree of penetration was 1.91 and 0.85 in the plasma 
and tissues. The authors concluded that the standard 
dose of vancomycin provide a low probability of 
obtaining targeted pharmacodynamic effects in the 
tissue of the lower limbs, connected with the wide 
variability in the tissue penetration of vancomycin in 
infectious complications of diabetic foot syndrome and 
cannot be predicted on the basis of determining the 
concentration of vancomycin in the blood [39]. 
When linezolid pharmacokinetic study 
demonstrated that the concentration after 8 hours and 
the maximum concentration (Cmax) were observed in 
plasma higher concentration (65,5 ± 21,2 mg * h / L and 
16.4 ± 4.6 mg / L) as compared to inflamed (36,3 ± 22,9 
mg * h / l and 6.6 ± 3.6 mg / l) and non-inflamed tissue 
(33,0 ± 17,7 mg * h / l and 6.7 ± 3.6 mg / l). These data 
show good penetration of linezolid into tissues 
infectious complications of the diabetic foot, but the 
therapeutic effect can occur delayed [40]. 
A study of linezolid concentrations in infected 
tissues and blood plasma in patients with isolated 
Staphylococcus aureus. This research characterized 
by a reduced susceptibility to vancomycin in patients 
with peripheral vascular disease and infectious 
complications, requiring surgery.  It is shown that the 
concentration of linezolid in the tissues of 51% (from 
18% to 78%), leads to the conclusion that the 
effectiveness of linezolid in the treatment of MRSA 
patients with diabetic foot with reduced 
concentrations of the drug at the site of blood flow 
disturbances [41].  
It has been studied the pharmacokinetics and 
pharmacodynamics of linezolid and trimethoprim / 
sulfamethoxazole high (320/1600 mg) and standard 
(160/800 mg) dose. For the average ratio of linezolid 
tissue / plasma was 0.46 with a standard dose of 1.2 
and at a high dose. For trimethoprim is 0.23 and 0.36 
respectively. The data obtained showed good 
penetration in soft tissue in patients with DFI and 
bactericidal activity against Staphylococcus aureus 
and β-haemolytic streptococci [42]. 
In the Austrian researchers demonstrated in 
patients with osteomyelitis applying microdialysis 
equilibrium between the plasma and tissue 
concentrations of daptomycin in the application in 
plasma reached approximately 2 hours after infusion. 
When this ratio average area under the 
pharmacokinetic curve (AUC) for the plasma AUC 
tissue after 16 hours reached 1.44 for healthy tissue 
to 0.98 inflamed subcutaneous adipose tissue and 
bone to 1.08. These results can be regarded as an 
effective means of treating patients with infectious 
complications of diabetic foot and osteomyelitis [43].  
In the study of tissue concentrations of 
ceftazidime dose of 2 g bolus injected intravenously 
30 minutes before surgery in patients with diabetes 
and without undergoing lower limb amputation, 
showed no difference in the concentration of 
ceftazidime. As a result of multiple regression 
analysis showed that the main factor determining the 
concentration in the bone and soft tissues is tissue 
perfusion, which will amount to 40-47% 
concentration in the studied tissues [44].  
It is shown that the introduction of ertapenem 
intravenously at a dose of 1.0 after 8 hours ego 
concentration, determined at a microdialysis in the soft 
tissues in patients with DFIs did not differ from the 
registered concentration in healthy volunteers [45].  
When studying tigecycline degree of penetration 
into the bone tissue revealed that the ratio of the bone 
tissue / serum was 4.77, which confirms the 
penetration of tigecycline into bone tissue [46].  
Thus, in the clinic of infectious complications of 
the diabetic foot are important microbiological 
population-geographical features of the studied 
pathology. These researchers necessitate constant of 
at the local level of microbiological monitoring of the 
structure of pathological agents with the assessment 
of the sensitivity of the microorganisms allocated to 
the appointed treatment in the early stages of 
infectious complications of diabetic foot infections 
according to the degree of penetration of 
antimicrobial chemotherapeutic agents in bone and 
soft tissue low limbs. 
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